With the introduction of the "Healthy China 2030" planning outline and the continuous improvement of the policy environment, China's pharmaceutical innovation industry continues to release vitality, and also attracts multinational pharmaceutical companies to increase the layout of China's pharmaceutical market
.
According to public information, at the upcoming fifth CIIE, many multinational pharmaceutical companies, including GSK, Merck, Uniratio, Amgen, Gilead, AstraZeneca, etc.
, will appear and bring more innovative products into the Chinese market
.
GSK
This year marks the first time GSK has appeared
in a new identity since the completion of the split.
It is reported that GSK's blockbuster products will also appear at the Expo with new indications, including the newly approved innovative biological agent for lupus nephritis, the first imported HPV vaccine in China to be approved for the two-dose vaccination program for girls aged 9-14 years, and the approval to expand the indication extension to the stable conversion of HIV-infected patients AIDS monolithic dual-drug treatment regimen Dovito
.
Merck
Public information shows that at this Expo, the blockbuster product of "old friend" Merck and Cod, the anti-new coronavirus oral drug monogravir, will be unveiled
.
Not long ago, Merck and China National Pharmaceutical Group Co.
, Ltd.
jointly announced "Holding Hands", and Merck granted Sinopharm the distribution right and exclusive import right of monolavir jointly developed by Merck and Ridgeback; Sinopharm China Biotech will actively promote localized production and supply
after obtaining the transfer of Merck monolavir technology.
Ushibi
Usby's first participation in the Expo, the company will bring a number of milestone drugs under development, as well as unique and differentiated innovative therapies that have been marketed overseas and have not yet been approved in China, including the world's only dual-mechanism osteoporosis treatment monoclonal antibody Evenity®, the epilepsy emergency innovative drug Staccato that has been recognized as a "breakthrough treatment" in China, and the world's first highly selective IL-17A/F inhibitor Bimzelx approved for moderate to severe plaque psoriasis, The treatment of rare epilepsy syndromes in children, Fintepla® (fenfluramine oral solution), and Zilucoplan and Rozanolixizumab, two "orphan drugs"
for the treatment of myasthenia gravis with different mechanisms.
Amgen
Amgen is also a "new friend" of the Expo, which will unveil two blockbuster products, namely eloumab for the treatment of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, and China's first and only approved fully human RANKL inhibitor denosumab injection 60mg, which is mainly used to treat osteoporosis
in postmenopausal women at high risk of fracture.
Gilead
This year marks Gilead's fifth year in the Chinese market, and the company is positioning oncology drugs as the "second growth curve"
in China.
At this Expo, the company will bring the world's first and only approved targeted trop-2 antibody conjugate drug gosastuzumab for the treatment of relapsed or refractory metastatic triple-negative breast cancer
.
Gosatuzumab was approved in China in June this year and is about to be marketed
.
AstraZeneca
AstraZeneca will bring four innovative drugs, including two blockbuster oncology innovative drugs, namely Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, and Calquence
for chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed refractory adult mantle cell lymphoma.
epilogue
In recent years, with the acceleration of changes in the global pharmaceutical market, multinational pharmaceutical companies have continued to
take new actions such as "spin-off", "divestiture", "sale" and "layoff".
With the help of CIIE, multinational pharmaceutical companies will bring more innovative drugs to the Chinese market, which shows that they attach importance to and are optimistic about the Chinese market, and will also bring more treatment options
to domestic patients.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
